Publicaciones en colaboración con investigadores/as de Instituto de Investigaciones Biomédicas Alberto Sols (41)

2024

  1. Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 277

2023

  1. C/EBPβ Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson’s Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease

    Cells, Vol. 12, Núm. 5

  3. Neuroprotective properties of queen bee acid by autophagy induction

    Cell Biology and Toxicology, Vol. 39, Núm. 3, pp. 751-770

2022

  1. Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson’s Disease: The Implication of Lipid Droplets and Lipophagy

    Cells, Vol. 11, Núm. 15

  2. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. The immune system through the lens of alcohol intake and gut microbiota

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2020

  1. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease

    Aging, Vol. 12, Núm. 17, pp. 16690-16708

  2. Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s Disease

    Molecular Neurobiology, Vol. 57, Núm. 2, pp. 806-822

  3. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

2019

  1. New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 712-727

  2. Novel approaches for the treatment of alzheimer’s and parkinson’s disease

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

2018

  1. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 156, pp. 534-553

2017

  1. Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson's Disease

    ACS Omega, Vol. 2, Núm. 8, pp. 5215-5220

  2. CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease

    Scientific Reports, Vol. 7, Núm. 1

  3. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 731-748

  4. Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo

    Stem Cells, Vol. 35, Núm. 2, pp. 458-472

  5. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

    Journal of Medicinal Chemistry, Vol. 60, Núm. 12, pp. 4983-5001

  6. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: Role of C/EBPβ

    Journal of Neuroinflammation, Vol. 13, Núm. 1